Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report.

Abstract

We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide.

• Authors: Luigi Rossi, Giuseppe Cimino, Elisa Gozzi, Marsela Sinjari, Martina Brandi, Serena Ceddia, Antonella Cosimati, Lucrezia Raimondi, Antonella Fontana, Luca Filippi, Oreste Bagni, Gian Paolo Spinelli
• Journal: Case reports in oncology (Case Rep Oncol) 2021 Jan-Apr Vol. 14 Issue 1 Pg. 634-640 ISSN: 1662-6575 [Print] Switzerland
• PMID: 33976646 (Publication Type: Case Reports)
• Copyright: Copyright © 2021 by S. Karger AG, Basel.